How many insider trades does FilingIQ track for CBUS?

FilingIQ tracks 151 Form 4 insider transactions for CBUS (Cibus, Inc.), covering filings from May 31, 2023 onwards. 19 of those were filed in the last 90 days.

Are CBUS insiders net buyers or net sellers?

Across the full Form 4 history for CBUS, 2 transactions (1%) were open-market purchases and 65 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CBUS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CBUS in?

Cibus, Inc. (CBUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $182.56M.

CBUS insider trading

Healthcare

Cibus, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

151

Last 90 days

Buys / sells

1% / 43%

Market cap

$182.56M

About Cibus, Inc.

Cibus, Inc., an agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products. It focuses on trait productivity in the productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients, which enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company was formerly known as Calyxt, Inc. and changed its name to Cibus, Inc. in June 2023. Cibus, Inc. was founded in 2001 and is headquartered in San Diego, California.

Company website: www.cibus.com

CBUS insider activity at a glance

FilingIQ has scored 151 insider transactions for CBUS since May 31, 2023. The most recent filing in our index is dated Apr 24, 2026.

Across the full history, 2 open-market purchases and 65 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CBUS insider trades is 56.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CBUS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CBUS?: FilingIQ tracks 151 Form 4 insider transactions for CBUS (Cibus, Inc.), covering filings from May 31, 2023 onwards. 19 of those were filed in the last 90 days.
Are CBUS insiders net buyers or net sellers?: Across the full Form 4 history for CBUS, 2 transactions (1%) were open-market purchases and 65 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CBUS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CBUS in?: Cibus, Inc. (CBUS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $182.56M.

Methodology & sources

Every CBUS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.